Our tech and life sciences teams provide seamless expert advice for global companies and investors in the fast-growing digital health industry. Our clients are renowned investors, from prominent early-stage funds to the largest global venture capital firms, and ambitious global digital health companies who, with our support, are revolutionizing the industry.
Through our established investor network we create transformative funding solutions for clients at all business stages, creating substantial financial foundations for growth and on-going development.
With experts in the UK, Europe, the Middle East, and Asia, together with our key partner collaborations in the US, our specialist approach in the provision of finance and capital raising, regulatory and data privacy, and IP, coupled with cross border expertise, provides the foundations for significant and sustainable global expansion for our clients. Our comprehensive awareness of the regulatory challenges facing emerging digital health companies both internally, and among ecosystem partners, is invaluable.
Supported by our data privacy and security teams, we successfully resolve personal data issues particular to digital and app-based devices and the broader regulatory challenges faced by our clients within a rapidly changing industry.
Similarly, our highly regarded IP team helps digital health companies achieve important milestones by securing, developing, and protecting valuable IP assets. This includes restructuring and executing sophisticated agreements and collaborations, partnerships and licensing agreements, and acquiring and divesting valuable businesses through strategic M&A.
Advised Protembis GmbH, the Aachen-based medical technology start-up, on financing by the European Investment Bank who granted the company a venture debt facility totalling EUR 20 million.
Press releaseAdvised Healx, an AI-enabled, clinical-stage biotech company specializing in rare diseases based in Cambridge UK, on its $47 million Series C funding. The funding was co-led by Silicon Valley-based R42 Group and Atomico, one of Europe’s largest venture capital firms, with participation from new and existing investors including Balderton, Jonathan Milner, Global Brain, btov, Ayana Capital, o2h and VU Venture Partners.
Press releaseAdvising Biomodal (formerly Cambridge Epigenetix) on its US$88 million Series D funding round to advance best-in-class DNA sequencing technology platform
Press releaseBabylon Health, a UK-based digital health subscription provider, on its USD550m fundraising to support expansion into the US and Asia. This is the largest ever fundraising in the European or US digital health sector and values Babylon at over USD2bn. Investors included PIF, ERGO Fund, Kinnevik and Vostok New Ventures.
Press releaseActualités et publications récentes
France renews its simplified anti-gift conventions – what life sciences companies operating in France need to know
France enforces one of Europe's strictest anti-gift regimes, broadly prohibiting any benefit to healthcare professionals, in particular. Within this framework, simplified conventions offer a practical derogation — allowing companies to bundle hospitality declarations into a single filing. These conventions have just been renewed for another two years, with notable developments: COMIDENT (dental sector) joins as a signatory and a new two-month deadline applies for participant list submissions for certain types of convention.
par Annabelle Lebaudy et Marine Boullenger
5 de 9 Publications
Case law – VfGH on the eImpfpass and central vaccination register
The Austrian Constitutional Court rejected challenges to the eImpfpass and central vaccination register on procedural grounds. The decision leaves the register in place, but highlights the role of data protection remedies in digital health infrastructure.
6 de 9 Publications
EHDS implementation: preparing for health data access and reuse
EHDS implementation has begun. For life sciences companies, the key issue is how controlled access to health data, secondary use, AI training and data protection governance will work in practice – and what should be prepared before 2029.
2 de 9 Publications
Advising Nuclera on its extended Series C funding to US$87 million
Guidance to manufacturers withdrawing a medical device from the EU market
Medical product availability and healthcare safety are becoming increasingly important talking points. This is also reflected in the EU regulations on medical devices. Although the provisions may seem straightforward their vagueness may give rise to significant doubts as to which situations they will apply to in practice.
par Bartosz Świdrak
4 de 5 Publications